Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma

C Y Cheah; John F. Seymour; Michael Dickinson

doi:10.2217/ijh.14.15

Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma

C Y Cheah
, John F. Seymour
, Michael Dickinson

Research output: Contribution to journal › Article › peer-review

Abstract

CNS relapse is a devastating and frequently lethal complication in patients with lymphoma, and selecting patients to receive CNS-directed prophylaxis is a common and frequently challenging decision for the clinician. Histologic subtype, anatomic location, molecular and clinical risk factors may all be used to stratify patients for CNS risk. In this paper we focus on these issues and attempt to provide practical guidance for the clinician in selecting which patients with lymphoma may benefit from CNS prophylaxis. 2014 Future Medicine Ltd.

Original language	English
Pages (from-to)	189-201
Number of pages	13
Journal	International Journal of Hematologic Oncology
Volume	3
Issue number	3
DOIs	https://doi.org/10.2217/ijh.14.15
Publication status	Published - 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2217/ijh.14.15

Cite this

@article{7ad89a882ac74167a6d1ef24d952e355,

title = "Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma",

abstract = "CNS relapse is a devastating and frequently lethal complication in patients with lymphoma, and selecting patients to receive CNS-directed prophylaxis is a common and frequently challenging decision for the clinician. Histologic subtype, anatomic location, molecular and clinical risk factors may all be used to stratify patients for CNS risk. In this paper we focus on these issues and attempt to provide practical guidance for the clinician in selecting which patients with lymphoma may benefit from CNS prophylaxis. 2014 Future Medicine Ltd.",

keywords = "B cell lymphoma, Burkitt lymphoma, Human immunodeficiency virus infection, NK T cell lymphoma, adrenal gland, albumin/ec [Endogenous Compound], article, bleomycin, bone marrow, breast, cancer combination chemotherapy, central nervous system, central nervous system disease, central nervous system prophylaxis, central nervous system relapse, cyclophosphamide, cytarabine, disease course, doxorubicin, epidural space, human, intravascular b cell lymphoma, kidney, lactate dehydrogenase blood level, lactate dehydrogenase/ec [Endogenous Compound], large cell lymphoma, liver, lung, mantle cell lymphoma, methotrexate, nasopharynx, non-Hodgkin lymphoma, nonhodgkin lymphoma, ovary, pancreas, paraaortic lymph node, paranasal sinus, prednisolone, primary mediastinal B cell lymphoma, priority journal, prophylaxis, relapse, risk factor, rituximab, salivary gland, testis, thyroid gland, vincristine, vindesine",

author = "Cheah, \{C Y\} and Seymour, \{John F.\} and Michael Dickinson",

year = "2014",

doi = "10.2217/ijh.14.15",

language = "English",

volume = "3",

pages = "189--201",

journal = "International Journal of Hematologic Oncology",

issn = "2045-1393",

publisher = "Future Medicine Ltd",

number = "3",

}

TY - JOUR

T1 - Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma

AU - Cheah, C Y

AU - Seymour, John F.

AU - Dickinson, Michael

PY - 2014

Y1 - 2014

N2 - CNS relapse is a devastating and frequently lethal complication in patients with lymphoma, and selecting patients to receive CNS-directed prophylaxis is a common and frequently challenging decision for the clinician. Histologic subtype, anatomic location, molecular and clinical risk factors may all be used to stratify patients for CNS risk. In this paper we focus on these issues and attempt to provide practical guidance for the clinician in selecting which patients with lymphoma may benefit from CNS prophylaxis. 2014 Future Medicine Ltd.

AB - CNS relapse is a devastating and frequently lethal complication in patients with lymphoma, and selecting patients to receive CNS-directed prophylaxis is a common and frequently challenging decision for the clinician. Histologic subtype, anatomic location, molecular and clinical risk factors may all be used to stratify patients for CNS risk. In this paper we focus on these issues and attempt to provide practical guidance for the clinician in selecting which patients with lymphoma may benefit from CNS prophylaxis. 2014 Future Medicine Ltd.

KW - B cell lymphoma

KW - Burkitt lymphoma

KW - Human immunodeficiency virus infection

KW - NK T cell lymphoma

KW - adrenal gland

KW - albumin/ec [Endogenous Compound]

KW - article

KW - bleomycin

KW - bone marrow

KW - breast

KW - cancer combination chemotherapy

KW - central nervous system

KW - central nervous system disease

KW - central nervous system prophylaxis

KW - central nervous system relapse

KW - cyclophosphamide

KW - cytarabine

KW - disease course

KW - doxorubicin

KW - epidural space

KW - human

KW - intravascular b cell lymphoma

KW - kidney

KW - lactate dehydrogenase blood level

KW - lactate dehydrogenase/ec [Endogenous Compound]

KW - large cell lymphoma

KW - liver

KW - lung

KW - mantle cell lymphoma

KW - methotrexate

KW - nasopharynx

KW - non-Hodgkin lymphoma

KW - nonhodgkin lymphoma

KW - ovary

KW - pancreas

KW - paraaortic lymph node

KW - paranasal sinus

KW - prednisolone

KW - primary mediastinal B cell lymphoma

KW - priority journal

KW - prophylaxis

KW - relapse

KW - risk factor

KW - rituximab

KW - salivary gland

KW - testis

KW - thyroid gland

KW - vincristine

KW - vindesine

U2 - 10.2217/ijh.14.15

DO - 10.2217/ijh.14.15

M3 - Article

C2 - 2014516459

SN - 2045-1393

VL - 3

SP - 189

EP - 201

JO - International Journal of Hematologic Oncology

JF - International Journal of Hematologic Oncology

IS - 3

ER -

Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this